Proteomic profiling of high risk medulloblastoma reveals functional biology

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14584-14595

  Staal, Jerome A ^a   Lau, Ling San ^a   Zhang, Huizhen ^a   Ingram, Wendy J ^b   Hallahan, Andrew R ^b   Northcott, Paul A ^c   Pfister, Stefan M ^c   Wechsler Reya, Robert J ^d   Rusert, Jessica M ^d   Taylor, Michael D ^e   Cho, Yoon Jae ^f   Packer, Roger J ^a   Brown, Kristy J ^a   Rood, Brian R ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d BURNHAM INSTITUTE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; cMYC; Glycolysis; Medulloblastoma; Proteomics

Indexed keywords

DEAD BOX PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN AB; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H1; MYC PROTEIN; PYRUVATE KINASE; SERINE ARGININE RICH PROTEIN; SERINE ARGININE RICH PROTEIN 2; SERINE ARGININE RICH PROTEIN 7; TRANSCRIPTION FACTOR OTX2; UNCLASSIFIED DRUG; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDULLOBLASTOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; VALIDATION PROCESS; CEREBELLUM TUMOR; GENETICS; MASS SPECTROMETRY; PATHOLOGY; PROCEDURES; PROTEOMICS; RISK FACTOR; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; HUMANS; MASS SPECTROMETRY; MEDULLOBLASTOMA; PROTEOMICS; RISK FACTORS;

EID: 84931053217     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3927     Document Type: Article

References (26)

1. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M and Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta neuropathologica. 2012; 123:465-472.
2. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:1424-1430.
3. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S and Taylor MD. Medulloblastoma Comprises Four Distinct Molecular Variants. J Clin Oncol. 2011; 29:1408-1414.
4. Pizer B, Donachie PH, Robinson K, Taylor RE, Michalski A, Punt J, Ellison DW and Picton S. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. Eur J Cancer. 2011; 47:1389-1397.
5. Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schuller U, Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology. 2013; 14:1200-1207.
6. Deeb SJ, D'Souza RC, Cox J, Schmidt-Supprian M and Mann M. Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics. 2012; 11:77-89.
7. Aebersold R and Mann M. Mass spectrometry-based proteomics. Nature. 2003; 422:198-207.
8. Cox J and Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annual review of biochemistry. 2011; 80:273-299.
9. Nilsson T, Mann M, Aebersold R, Yates JR, 3rd, Bairoch A and Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nature methods. 2010; 7:681-685.
10. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR and Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods. 2010; 7:383-385.
11. Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, Luu B, Yao Y, Wang X, Dubuc AM, Garzia L, Peacock J, Mack SC, Wu X, Rolider A, Morrissy AS, et al. Cytogenetic prognostication within medulloblastoma subgroups. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32:886-896.
12. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta neuropathologica. 2012; 123:473-484.
13. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P and von Mering C. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic acids research. 2009; 37(Database issue):D412-416.
14. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stutz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012; 488:49-56.
15. David CJ, Chen M, Assanah M, Canoll P and Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010; 463:364-368.
16. Cantor JR and Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer discovery. 2012; 2:881-898.
17. Chaneton B and Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends in biochemical sciences. 2012; 37:309-316.
18. Dang CV. Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. Genes & cancer. 2010; 1:526-531.
19. Dang CV. MYC on the path to cancer. Cell. 2012; 149:22-35.
20. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ, Kurhanewicz J, Vigneron DB and Goga A. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell metabolism. 2011; 14:131-142.
21. Roussel MF and Robinson GW. Role of MYC in Medulloblastoma. Cold Spring Harbor perspectives in medicine. 2013; 3(11).
22. Bunt J, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R and Kool M. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma. PloS one. 2011; 6:e26058.
23. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012; 488:100-105.
24. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, et al. Medulloblastoma exome sequencing uncovers subtypespecific somatic mutations. Nature. 2012; 488:106-110.
25. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012; 488:43-48.
26. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM and Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PloS one. 2013; 8:e57610.